Company

Elcelyx Therapeutics

As of the edition of 20 October 2026, Elcelyx Therapeutics runs 1 drug; it is on route A at 50 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet1
Total1

Where it needs a new molecule

Route A at 50 targets, route B at 0 targets.

Three of its 50 rows, by target and route
TargetRoute
GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrialRoute A
NDUFS8 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrialRoute A
COXFA4 Cytochrome c oxidase subunit FA4Route A

All 50 rows on route A or B

In the product

50 company-target rows on route A or B; 47 are not shown here, and no score is.

Where its trials are

  • Hormones: 1 trials led
  • Nutrition and metabolism: 1 trials led